1. Home
  2. SBI vs IMUX Comparison

SBI vs IMUX Comparison

Compare SBI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBI
  • IMUX
  • Stock Information
  • Founded
  • SBI 1992
  • IMUX 2016
  • Country
  • SBI United States
  • IMUX United States
  • Employees
  • SBI N/A
  • IMUX N/A
  • Industry
  • SBI Finance/Investors Services
  • IMUX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SBI Finance
  • IMUX Health Care
  • Exchange
  • SBI Nasdaq
  • IMUX Nasdaq
  • Market Cap
  • SBI 106.2M
  • IMUX 94.9M
  • IPO Year
  • SBI N/A
  • IMUX N/A
  • Fundamental
  • Price
  • SBI $7.57
  • IMUX $1.01
  • Analyst Decision
  • SBI
  • IMUX Strong Buy
  • Analyst Count
  • SBI 0
  • IMUX 6
  • Target Price
  • SBI N/A
  • IMUX $13.20
  • AVG Volume (30 Days)
  • SBI 39.5K
  • IMUX 1.3M
  • Earning Date
  • SBI 01-01-0001
  • IMUX 05-20-2025
  • Dividend Yield
  • SBI 4.52%
  • IMUX N/A
  • EPS Growth
  • SBI N/A
  • IMUX N/A
  • EPS
  • SBI N/A
  • IMUX N/A
  • Revenue
  • SBI N/A
  • IMUX N/A
  • Revenue This Year
  • SBI N/A
  • IMUX N/A
  • Revenue Next Year
  • SBI N/A
  • IMUX N/A
  • P/E Ratio
  • SBI N/A
  • IMUX N/A
  • Revenue Growth
  • SBI N/A
  • IMUX N/A
  • 52 Week Low
  • SBI $6.96
  • IMUX $0.83
  • 52 Week High
  • SBI $8.00
  • IMUX $2.11
  • Technical
  • Relative Strength Index (RSI)
  • SBI 48.71
  • IMUX 46.64
  • Support Level
  • SBI $7.52
  • IMUX $0.95
  • Resistance Level
  • SBI $7.75
  • IMUX $1.22
  • Average True Range (ATR)
  • SBI 0.07
  • IMUX 0.12
  • MACD
  • SBI 0.02
  • IMUX -0.01
  • Stochastic Oscillator
  • SBI 50.00
  • IMUX 16.67

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: